GlassScriptPhysician profile
Donald B Franklin
NPI 1053319343
$533.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $37.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $128.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $100.37 | 2019 | |
| Vifor Pharma, INC. | $59.56 | 2019-2020 | |
| Amgen INC. | $57.02 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $49.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.64 | 2019 | |
| Horizon Therapeutics Plc | $27.46 | 2019 | |
| Shire North American Group INC | $14.91 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.22 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.